Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19504856 | 0.87 | CHRM2 (0.50) | CHRM2CARM1PRMT6PRMT8 | |
| SCHEMBL841236 | 0.86 | CA12 (0.39) | CHRM2CA12CA2CA3CA4 | |
| SCHEMBL22702535 | 0.83 | CHRM2 (0.36) | CHRM2 | |
| SCHEMBL29580662 | 0.83 | CA12 (0.44) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29580659 | 0.83 | CA12 (0.44) | CA12CA2CA3CA4CA6 | |
| SCHEMBL13649903 | 0.81 | CHRM2 (0.36) | CHRM2CA12CA2CA3CA4 | |
| SCHEMBL15075 | 0.80 | — | — | |
| SCHEMBL19705235 | 0.77 | CHRM2 (0.45) | CHRM2 | |
| SCHEMBL31034365 | 0.76 | CHRM2 (0.53) | CHRM2CARM1PRMT6PRMT8CA12 | |
| SCHEMBL1262347 | 0.76 | CHRM2 (0.53) | CHRM2CARM1PRMT6PRMT8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-11584762-B1 | Near-infrared fluorescent indicators for lysosome and application thereof | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210154148-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-05-27 | — | — | US | disclosed |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154148-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | CHRM2 4880/4885CARM1 4123/4885PRMT6 3707/4885 |
| US-11584762-B1 | Near-infrared fluorescent indicators for lysosome and application thereof | LAMP2, LAMP1, LIPA | CHRM2 4039/4885CARM1 3712/4885PRMT6 4075/4885 |
| US-20230027864-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | CHRM2 4821/4885CARM1 2943/4885PRMT6 2571/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | CHRM2 3020/4885CARM1 156/4885PRMT6 473/4885 |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | CHRM2 4821/4885CARM1 2943/4885PRMT6 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.